SEC 13F Intelligence

Managers / Q2 2022 · view latest →

RHO CAPITAL PARTNERS INC

CIK 0001020455 · 152 WEST 57TH STREET, 23RD FLOOR, NEW YORK, NY, 10019 · 212-751-6677

Reported Value
$59M
Q2 2022
Positions
4
Filings on Record
18
2019–present window
Filed
Aug 1, 2022
original filing

Summary

Rho Capital Partners Inc reported $59M in U.S.-listed holdings across 4 positions for Q2 2022.

The portfolio is heavily concentrated: Chargepoint alone accounts for 94.3% of reported value.

Compared with Q1 2022, the fund opened 0 new positions and exited 2.

Portfolio Metrics

Turnover
+0.1%
vs prior filed quarter
Largest Position
+94.3%
Chargepoint

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $94MQ1 ’19Q2 ’19: $144MQ3 ’19: $119MQ4 ’19: $132MQ4 ’19Q1 ’20: $99MQ2 ’20: $154MQ3 ’20: $120MQ3 ’20Q4 ’20: $190MQ1 ’21: $1.0BQ2 ’21: $1.1BQ2 ’21Q3 ’21: $179MQ4 ’21: $154MQ1 ’22: $145MQ1 ’22Q2 ’22: $59MQ3 ’22: $63MQ4 ’22: $41MQ4 ’22Q2 ’23: $39MQ3 ’23: $20Mfilingsflow.com

Portfolio Composition

By security type
Other: 94.3%Common Stock: 5.7%
  • Other · 94.3% · $55M
  • Common Stock · 5.7% · $3M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NGM BIOPHARMACEUTICALS INCSOLD OUT3.77M0$57M$0
MERSANA THERAPEUTICS INCSOLD OUT796.5K0$3M$0
CHARGEPOINT HOLDINGS INCHELD+04.05M$25M$55M
SENSEONICS HLDGS INCHELD+0159.6K$150,000$164,000
LIVEONE INCHELD+03.72M+$149,000$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2022

4 positions
#IssuerClass% PortfolioValueShares
1CHARGEPOINT HOLDINGS INCCOM CL A94.30%$55M4.05M
2LIVEONE INCCOM5.42%$3M3.72M
3SENSEONICS HLDGS INCCOM0.28%$164,000159.6K
4MERSANA THERAPEUTICS INCCOM0.00%$00

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2023$20M3Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$39M3Aug 8, 202313F-HRchanges · EDGAR ↗
Q4 2022$41M3Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$63M4Nov 4, 202213F-HRchanges · EDGAR ↗
Q2 2022$59M4Aug 1, 202213F-HRchanges · EDGAR ↗
Q1 2022$145M5May 11, 202213F-HRchanges · EDGAR ↗
Q4 2021$154M5Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$179M7Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.1B7Aug 12, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.0B7May 13, 202113F-HRchanges · EDGAR ↗
Q4 2020$190M5Feb 10, 202113F-HRchanges · EDGAR ↗
Q3 2020$120M5Nov 23, 202013F-HRchanges · EDGAR ↗
Q2 2020$154M5Aug 7, 202013F-HRchanges · EDGAR ↗
Q1 2020$99M5May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$132M5Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$119M5Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$144M5Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$94M5May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.